Search

Your search keyword '"Anastasiou, Panayiotis"' showing total 20 results
Start Over Author "Anastasiou, Panayiotis"
20 results on '"Anastasiou, Panayiotis"'

2. Antibodies against endogenous retroviruses promote lung cancer immunotherapy

Author

Ng, Kevin W., Boumelha, Jesse, Enfield, Katey S. S., Almagro, Jorge, Cha, Hongui, Pich, Oriol, Karasaki, Takahiro, Moore, David A., Salgado, Roberto, Sivakumar, Monica, Young, George, Molina-Arcas, Miriam, de Carné Trécesson, Sophie, Anastasiou, Panayiotis, Fendler, Annika, Au, Lewis, Shepherd, Scott T. C., Martínez-Ruiz, Carlos, Puttick, Clare, Black, James R. M., Watkins, Thomas B. K., Kim, Hyemin, Shim, Seohee, Faulkner, Nikhil, Attig, Jan, Veeriah, Selvaraju, Magno, Neil, Ward, Sophia, Frankell, Alexander M., Al Bakir, Maise, Lim, Emilia L., Hill, Mark S., Wilson, Gareth A., Cook, Daniel E., Birkbak, Nicolai J., Behrens, Axel, Yousaf, Nadia, Popat, Sanjay, Hackshaw, Allan, Hiley, Crispin T., Litchfield, Kevin, McGranahan, Nicholas, Jamal-Hanjani, Mariam, Larkin, James, Lee, Se-Hoon, Turajlic, Samra, Swanton, Charles, Downward, Julian, and Kassiotis, George

Published
2023
Full Text
View/download PDF

3. Spatial proteomic analysis of a lung cancer model reveals regulatory T cells attenuate KRAS-G12C inhibitor-induced immune responses

Author

Cole, Megan, primary, Anastasiou, Panayiotis, additional, Lee, Claudia, additional, Moore, Chris, additional, Mugarza, Edurne, additional, Jones, Martin, additional, Valand, Karshma, additional, Rana, Sareena, additional, Colliver, Emma, additional, Angelova, Mihaela, additional, Enfield, Katey, additional, Magness, Alastair, additional, Mullokandov, Asher, additional, Kelly, Gavin, additional, de Gruijl, Tanja, additional, Molina-Arcas, Miriam, additional, Swanton, Charles, additional, Downward, Julian, additional, and van Maldegem, Febe, additional

Published
2024
Full Text
View/download PDF

5. Combining RASG12C(ON) inhibitor with SHP2 inhibition sensitises immune excluded lung tumours to immune checkpoint blockade: a strategy for turning cold tumours hot

Author

Anastasiou, Panayiotis, primary, Moore, Christopher, additional, Rana, Sareena, additional, de Castro, Andrea, additional, Tomaschko, Mona, additional, Boumelha, Jesse, additional, Mugarza, Edurne, additional, Blaj, Cristina, additional, de Carné, Sophie, additional, Goldstone, Robert, additional, Smith, Jacqueline A.M., additional, Quintana, Elsa, additional, Molina-Arcas, Miriam, additional, and Downward, Julian, additional

Published
2024
Full Text
View/download PDF

7. In vivo CRISPR screen identifies KRAS-induced COX-2 as a driver of immune evasion and immunotherapy resistance in lung cancer

Author

Boumelha, Jesse, primary, de Castro, Andrea, additional, Bah, Nourdine, additional, Cha, Hongui, additional, de Carné Trécesson, Sophie, additional, Rana, Sareena, additional, Anastasiou, Panayiotis, additional, Mugarza, Edurne, additional, Moore, Christopher, additional, Goldstone, Robert, additional, East, Phil, additional, Litchfield, Kevin, additional, Lee, Se-Hoon, additional, Molina-Arcas, Miriam, additional, and Downward, Julian, additional

Published
2023
Full Text
View/download PDF

9. Figure S10 from MYC Instructs and Maintains Pancreatic Adenocarcinoma Phenotype

Author

Sodir, Nicole M., primary, Kortlever, Roderik M., primary, Barthet, Valentin J.A., primary, Campos, Tania, primary, Pellegrinet, Luca, primary, Kupczak, Steven, primary, Anastasiou, Panayiotis, primary, Swigart, Lamorna Brown, primary, Soucek, Laura, primary, Arends, Mark J., primary, Littlewood, Trevor D., primary, and Evan, Gerard I., primary

Published
2023
Full Text
View/download PDF

10. Data from MYC Instructs and Maintains Pancreatic Adenocarcinoma Phenotype

Author

Sodir, Nicole M., primary, Kortlever, Roderik M., primary, Barthet, Valentin J.A., primary, Campos, Tania, primary, Pellegrinet, Luca, primary, Kupczak, Steven, primary, Anastasiou, Panayiotis, primary, Swigart, Lamorna Brown, primary, Soucek, Laura, primary, Arends, Mark J., primary, Littlewood, Trevor D., primary, and Evan, Gerard I., primary

Published
2023
Full Text
View/download PDF

11. Table S1 from MYC Instructs and Maintains Pancreatic Adenocarcinoma Phenotype

Author

Sodir, Nicole M., primary, Kortlever, Roderik M., primary, Barthet, Valentin J.A., primary, Campos, Tania, primary, Pellegrinet, Luca, primary, Kupczak, Steven, primary, Anastasiou, Panayiotis, primary, Swigart, Lamorna Brown, primary, Soucek, Laura, primary, Arends, Mark J., primary, Littlewood, Trevor D., primary, and Evan, Gerard I., primary

Published
2023
Full Text
View/download PDF

12. Antibodies against endogenous retroviruses promote lung cancer immunotherapy

Author

Ng, Kevin W, Boumelha, Jesse, Enfield, Katey SS, Almagro, Jorge, Cha, Hongui, Pich, Oriol, Karasaki, Takahiro, Moore, David A, Salgado, Roberto, Sivakumar, Monica, Young, George, Molina-Arcas, Miriam, de Carné Trécesson, Sophie, Anastasiou, Panayiotis, Fendler, Annika, Au, Lewis, Shepherd, Scott TC, Martínez-Ruiz, Carlos, Puttick, Clare, Black, James RM, Watkins, Thomas BK, Kim, Hyemin, Shim, Seohee, Faulkner, Nikhil, Attig, Jan, Veeriah, Selvaraju, Magno, Neil, Ward, Sophia, Frankell, Alexander M, Al Bakir, Maise, Lim, Emilia L, Hill, Mark S, Wilson, Gareth A, Cook, Daniel E, Birkbak, Nicolai J, Behrens, Axel, Yousaf, Nadia, Popat, Sanjay, Hackshaw, Allan, Consortium, TRACERx, Consortium, CAPTURE, Hiley, Crispin T, Litchfield, Kevin, McGranahan, Nicholas, Jamal-Hanjani, Mariam, Larkin, James, Lee, Se-Hoon, Turajlic, Samra, Swanton, Charles, Downward, Julian, and Kassiotis, George

Subjects
Model organisms, Lung Neoplasms, Immunology, Gene Expression, Adenocarcinoma of Lung, Infectious Disease, Antibodies, Cohort Studies, Mice, Signalling & Oncogenes, Ecology,Evolution & Ethology, Carcinoma, Non-Small-Cell Lung, Tumor Microenvironment, Animals, Humans, Lung, Computational & Systems Biology, Chemical Biology & High Throughput, B-Lymphocytes, Human Biology & Physiology, Stem Cells, FOS: Clinical medicine, Endogenous Retroviruses, Genome Integrity & Repair, Cell Biology, Tumour Biology, Disease Models, Animal, Cell Cycle & Chromosomes, Immunotherapy, Genetics & Genomics
Abstract

B cells are frequently found in the margins of solid tumours as organized follicles in ectopic lymphoid organs called tertiary lymphoid structures (TLS)1,2. Although TLS have been found to correlate with improved patient survival and response to immune checkpoint blockade (ICB), the underlying mechanisms of this association remain elusive1,2. Here we investigate lung-resident B cell responses in patients from the TRACERx 421 (Tracking Non-Small-Cell Lung Cancer Evolution Through Therapy) and other lung cancer cohorts, and in a recently established immunogenic mouse model for lung adenocarcinoma3. We find that both human and mouse lung adenocarcinomas elicit local germinal centre responses and tumour-binding antibodies, and further identify endogenous retrovirus (ERV) envelope glycoproteins as a dominant anti-tumour antibody target. ERV-targeting B cell responses are amplified by ICB in both humans and mice, and by targeted inhibition of KRAS(G12C) in the mouse model. ERV-reactive antibodies exert anti-tumour activity that extends survival in the mouse model, and ERV expression predicts the outcome of ICB in human lung adenocarcinoma. Finally, we find that effective immunotherapy in the mouse model requires CXCL13-dependent TLS formation. Conversely, therapeutic CXCL13 treatment potentiates anti-tumour immunity and synergizes with ICB. Our findings provide a possible mechanistic basis for the association of TLS with immunotherapy response. ispartof: NATURE vol:616 issue:7957 ispartof: location:England status: Published online

Published
2023
Full Text
View/download PDF

13. Therapeutic KRAS G12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers

Author

Mugarza, Edurne, primary, van Maldegem, Febe, additional, Boumelha, Jesse, additional, Moore, Christopher, additional, Rana, Sareena, additional, Llorian Sopena, Miriam, additional, East, Philip, additional, Ambler, Rachel, additional, Anastasiou, Panayiotis, additional, Romero-Clavijo, Pablo, additional, Valand, Karishma, additional, Cole, Megan, additional, Molina-Arcas, Miriam, additional, and Downward, Julian, additional

Published
2022
Full Text
View/download PDF

15. Therapeutic KRASG12C inhibition drives effective interferon-mediated anti-tumour immunity in immunogenic lung cancers

Author

Mugarza, Edurne, primary, van Maldegem, Febe, additional, Boumelha, Jesse, additional, Moore, Christopher, additional, Rana, Sareena, additional, Sopena, Miriam Llorian, additional, East, Philip, additional, Ambler, Rachel, additional, Anastasiou, Panayiotis, additional, Clavijo, Pablo Romero, additional, Valand, Karishma, additional, Cole, Megan, additional, Molina-Arcas, Miriam, additional, and Downward, Julian, additional

Published
2021
Full Text
View/download PDF

16. Preventing cancer by long-term partial Myc suppression

Author

Sodir, Nicole M., primary, Pellegrinet, Luca, additional, Kortlever, Roderik M., additional, Kwon, Yong-Won, additional, Kim, Shinseog, additional, Garcia, Daniel, additional, Perfetto, Alessandra, additional, Anastasiou, Panayiotis, additional, Swigart, Lamorna Brown, additional, Littlewood, Trevor D., additional, and Evan, Gerard I., additional

Published
2020
Full Text
View/download PDF

17. MYC Instructs and Maintains Pancreatic Adenocarcinoma Phenotype

Author

Sodir, Nicole M., primary, Kortlever, Roderik M., additional, Barthet, Valentin J.A., additional, Campos, Tania, additional, Pellegrinet, Luca, additional, Kupczak, Steven, additional, Anastasiou, Panayiotis, additional, Swigart, Lamorna Brown, additional, Soucek, Laura, additional, Arends, Mark J., additional, Littlewood, Trevor D., additional, and Evan, Gerard I., additional

Published
2020
Full Text
View/download PDF

18. Myc instructs and maintains pancreatic adenocarcinoma phenotype

Author

Evan, Gerard, Sodir, Nicole, Kortlever, Roderik, Barthet, Valentin JA, Campos, Tania, Pellegrinet, Luca, Kupczak, Steven, Anastasiou, Panayiotis, Brown Swigart, Lamorna, Soucek, Laura, Arends, Mark J, and Littlewood, Trevor D

Subjects
2 Aetiology, endocrine system diseases, Genes, myc, 32 Biomedical and Clinical Sciences, Prognosis, digestive system diseases, 3. Good health, 3204 Immunology, Pancreatic Neoplasms, Proto-Oncogene Proteins c-myc, Proto-Oncogene Proteins p21(ras), Pancreatic Cancer, Mice, Rare Diseases, Phenotype, FOS: Biological sciences, Genetics, 2.1 Biological and endogenous factors, Animals, Humans, Digestive Diseases, Cancer, Carcinoma, Pancreatic Ductal
Abstract

The signature features of pancreatic ductal adenocarcinoma (PDAC) are its fibroinflammatory stroma, poor immune activity and dismal prognosis. We show that acute activation of Myc in indolent PanIN epithelial cells in vivo is, alone, sufficient to trigger immediate release of instructive signals that together coordinate changes in multiple stromal and immune cell types and trigger transition to pancreatic adenocarcinomas that share all the characteristic stromal features of their spontaneous human counterpart. We also demonstrate that this Myc-driven PDAC switch is completely and immediately reversible: Myc deactivation/inhibition triggers meticulous disassembly of advanced PDAC tumor and stroma and concomitant death of tumor cells. Hence, both the formation and deconstruction of the complex PDAC phenotype are continuously dependent on a single, reversible Myc switch.

19. Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers.

Author

Mugarza, Edurne, van Maldegem, Febe, Boumelha, Jesse, Moore, Christopher, Rana, Sareena, Sopena, Miriam Llorian, East, Philip, Ambler, Rachel, Anastasiou, Panayiotis, Romero-Clavijo, Pablo, Valand, Karishma, Cole, Megan, Molina-Arcas, Miriam, and Downward, Julian

Subjects
*MACROPHAGE colony-stimulating factor, *T cells, *ANTIGEN presenting cells, *LUNG cancer, *GENETIC regulation, *RAS proteins
Abstract

The article presents a study on a therapeutic KRASG12C (glycine 12 to cysteine) inhibitor that drives effective interferon-mediated antitumor immunity in immunogenic lung cancers. It discusses that the in vivo KRASG12C inhibitor increases the T cell infiltration and activation. It also describes the mechanism of the KRASG12C inhibition reverses immunosuppression in several preclinical lung cancer models with varying levels of immunogenicity.

Published
2022
Full Text
View/download PDF

20. CRISPR-Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer.

Author

Boumelha J, de Castro A, Bah N, Cha H, de Carné Trécesson S, Rana S, Tomaschko M, Anastasiou P, Mugarza E, Moore C, Goldstone R, East P, Litchfield K, Lee SH, Molina-Arcas M, and Downward J

Subjects
Animals, Mice, Humans, Dinoprostone metabolism, Adenocarcinoma of Lung immunology, Adenocarcinoma of Lung genetics, Adenocarcinoma of Lung drug therapy, Adenocarcinoma of Lung pathology, Adenocarcinoma of Lung therapy, Tumor Microenvironment immunology, Immune Checkpoint Inhibitors pharmacology, Immune Checkpoint Inhibitors therapeutic use, Cell Line, Tumor, Mice, Inbred C57BL, Female, Lung Neoplasms genetics, Lung Neoplasms immunology, Lung Neoplasms pathology, Lung Neoplasms therapy, Lung Neoplasms drug therapy, Cyclooxygenase 2 metabolism, Cyclooxygenase 2 genetics, Proto-Oncogene Proteins p21(ras) genetics, CRISPR-Cas Systems, Drug Resistance, Neoplasm genetics, Immunotherapy methods
Abstract

Oncogenic KRAS impairs antitumor immune responses. As effective strategies to combine KRAS inhibitors and immunotherapies have so far proven elusive, a better understanding of the mechanisms by which oncogenic KRAS drives immune evasion is needed to identify approaches that could sensitize KRAS-mutant lung cancer to immunotherapy. In vivo CRISPR-Cas9 screening in an immunogenic murine lung cancer model identified mechanisms by which oncogenic KRAS promotes immune evasion, most notably via upregulation of immunosuppressive COX2 in cancer cells. Oncogenic KRAS potently induced COX2 in both mouse and human lung cancer, which was suppressed using KRAS inhibitors. COX2 acted via prostaglandin E2 (PGE2) to promote resistance to immune checkpoint blockade (ICB) in lung adenocarcinoma. Targeting COX2/PGE2 remodeled the tumor microenvironment by inducing proinflammatory polarization of myeloid cells and influx of activated cytotoxic CD8+ T cells, which increased the efficacy of ICB. Restoration of COX2 expression contributed to tumor relapse after prolonged KRAS inhibition. These results provide the rationale for testing COX2/PGE2 pathway inhibitors in combination with KRASG12C inhibition or ICB in patients with KRAS-mutant lung cancer. Significance: COX2 signaling via prostaglandin E2 is a major mediator of immune evasion driven by oncogenic KRAS that promotes immunotherapy and KRAS-targeted therapy resistance, suggesting effective combination treatments for KRAS-mutant lung cancer., (©2024 The Authors; Published by the American Association for Cancer Research.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results